clinical trial · NCT05786443
Safety and Efficacy of Empagliflozin in Hemodialysis
NYU Langone Health·phase2·active not recruiting·n = 60
End Stage Renal DiseaseEmpagliflozin 10 MGPlacebo
brief summary
A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
started
Jan 31, 2024
primary completion
Dec 30, 2026
completion
Dec 30, 2026
last updated
Nov 6, 2026
official title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol